Theratechnologies Inc. Common (THTX) Dividend History

Theratechnologies Inc. is a Canadian biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs. The company specializes in treatments for HIV/AIDS, oncology, and inflammatory diseases, with a particular emphasis on peptide-based therapies. Founded in 1987, Theratechnologies is known for its innovative approach to addressing serious health conditions through targeted biological treatments.

Website: https://www.theratech.com

Dividend History

Theratechnologies Inc. Common currently does not pay dividends

Company News

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

Theratechnologies received unsolicited acquisition proposals from Future Pak, but is in exclusive discussions with another potential acquirer. The company's board has formed a special committee to review the proposals and determine the best course of action for the company and its stakeholders.

GlobeNewswire Inc.
Theratechnologies réagit à la récente déclaration publique de Future Pak et annonce des discussions exclusives avec un autre acquéreur potentiel pour la vente de la Société

Theratechnologies has received two non-binding acquisition proposals from Future Pak, which were rejected. The company is now in exclusive discussions with another potential acquirer. A special committee is reviewing the proposals to determine the best course of action for the company and its shareholders.

GlobeNewswire Inc.
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert

US stock futures are trading lower after a three-day advance, as investors react cautiously to President Trump's mixed tariff signals. The market is looking more balanced, having moved from 'above-trend to on-trend', according to an expert.

Benzinga

Featured Companies: CISO GME HUMA QQQ SPY WINT
Theratechnologies Resumes Distribution of EGRIFTA SV®

Theratechnologies has resumed distribution of its HIV treatment EGRIFTA SV® after receiving correspondence from the FDA allowing the release of two recently manufactured batches. The FDA's review of the company's Prior Approval Supplement is ongoing, with an action goal date of April 18, 2025.

GlobeNewswire Inc.
Theratechnologies reprend la distribution d’EGRIFTA SV(MD)

Theratechnologies announced that it has resumed the distribution of EGRIFTA SV (tesamoreline for injection) in the United States after receiving communication from the FDA authorizing the release of two recently manufactured lots of the product. The company remains committed to providing EGRIFTA SV to people living with HIV.

GlobeNewswire Inc.

Dividend data last updated 06/06/2025 17:04:16 UTC